Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anouk K M Claessens

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|January 12, 2023
[A bleeding tumor on the scalp]Anouk K M Claessens, Jos G U Ridderbeks
Critical Reviews in Oncology/Hematology|June 30, 2020
The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practiceAnouk K M Claessens, Khava I E Ibragimova, Sandra M E Geurts, et al.
Breast Cancer Research and Treatment|November 30, 2019
The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancerAnouk K M Claessens, Reinier Timman, Jan J Busschbach, et al.
Acta Oncologica (Stockholm, Sweden)|March 7, 2020
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancerAnouk K M Claessens, Frans L G Erdkamp, Marta Lopez-Yurda, et al.
Acta Oncologica (Stockholm, Sweden)|February 10, 2022
Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancerAnouk K M Claessens, Jan J V Busschbach, Bram L T Ramaekers, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 21, 2020
Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE RegistryAnouk K M Claessens, Bram L T Ramaekers, Dorien J A Lobbezoo, et al.
Breast Cancer Research and Treatment|August 20, 2018
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)Anouk K M Claessens, Monique E M M Bos, Marta Lopez-Yurda, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Nederlands Tijdschrift Voor Geneeskunde|January 12, 2023
[A bleeding tumor on the scalp]Anouk K M Claessens, Jos G U Ridderbeks
Critical Reviews in Oncology/Hematology|June 30, 2020
The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practiceAnouk K M Claessens, Khava I E Ibragimova, Sandra M E Geurts, et al.
Breast Cancer Research and Treatment|November 30, 2019
The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancerAnouk K M Claessens, Reinier Timman, Jan J Busschbach, et al.
Acta Oncologica (Stockholm, Sweden)|March 7, 2020
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancerAnouk K M Claessens, Frans L G Erdkamp, Marta Lopez-Yurda, et al.
Acta Oncologica (Stockholm, Sweden)|February 10, 2022
Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancerAnouk K M Claessens, Jan J V Busschbach, Bram L T Ramaekers, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 21, 2020
Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE RegistryAnouk K M Claessens, Bram L T Ramaekers, Dorien J A Lobbezoo, et al.
Breast Cancer Research and Treatment|August 20, 2018
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)Anouk K M Claessens, Monique E M M Bos, Marta Lopez-Yurda, et al.
Pageof 1